Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

41. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. Full Text available with Trip Pro

Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time.To investigate associations between televised DTCA and testosterone testing and initiation in the United States.Ecologic study conducted in designated market areas (DMAs (...) ) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations.Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs.(1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection

2017 JAMA

42. Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet Full Text available with Trip Pro

Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet In obese men with lowered testosterone levels, testosterone treatment augments diet-associated loss of body fat.We hypothesized that testosterone treatment modulates circulating concentrations of hormonal mediators of fat mass and energy homeostasis in obese men undergoing a weight loss program.Prespecified secondary analysis of a randomized, double-blind, placebo-controlled trial.Tertiary (...) referral center.Obese men (body mass index ≥30 kg/m2) with a repeated total testosterone level ≤12 nmol/L.One hundred participants mean age 53 years (interquartile range 47 to 60 years) receiving 10 weeks of a very low-energy diet followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (cases, n = 49) or matching placebo (controls, n = 51). Eighty-two men completed the study.Between-group differences in leptin, adiponectin

2017 Journal of the Endocrine Society Controlled trial quality: predicted high

43. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. Full Text available with Trip Pro

Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. Recent studies have yielded conflicting results as to whether testosterone treatment increases cardiovascular risk.To test the hypothesis that testosterone treatment of older men with low testosterone slows progression of noncalcified coronary artery plaque volume.Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 (...) years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism who were enrolled in the Testosterone Trials between June 24, 2010, and June 9, 2014.Testosterone gel, with the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months.The primary outcome was noncalcified coronary artery plaque volume, as determined by coronary computed

2017 JAMA Controlled trial quality: predicted high

44. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Full Text available with Trip Pro

Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions.To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI).The Testosterone Trials (TTrials) were 7 trials (...) to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n = 394) or placebo (n = 394). A subgroup of 493 men met criteria for AAMI based on baseline subjective

2017 JAMA Controlled trial quality: predicted high

45. Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines

Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Published on: February 9, 2017 Project Number: RA0892-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of testosterone for patients with depression? What is the clinical effectiveness of testosterone for patients with post-traumatic stress disorder? What is the clinical effectiveness of testosterone for patients with fibromyalgia? What are the evidence-based guidelines for the use of testosterone for patients with depression, PTSD, or fibromyalgia? Key Message Two systematic reviews, two randomized controlled trials

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) Full Text available with Trip Pro

Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) Measurement of salivary testosterone (Sal-T) to assess androgen status offers important potential advantages in epidemiological research. The utility of the method depends on the interpretation of the results against robustly determined population distributions, which are currently lacking.To determine age-specific Sal-T

2017 Journal of the Endocrine Society

47. Testosterone treatment and risk of venous thromboembolism: population based case-control study. Full Text available with Trip Pro

Testosterone treatment and risk of venous thromboembolism: population based case-control study.  To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk. Population based case-control study SETTING:  370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality. 19 215 patients with confirmed venous thromboembolism (...) (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013. Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months. Rate ratios of venous thromboembolism in association with current

2016 BMJ

48. Testosterone Therapy Among Prostate Cancer Survivors Full Text available with Trip Pro

Testosterone Therapy Among Prostate Cancer Survivors The use of testosterone in men with a history of prostate cancer remains controversial in light of established findings linking androgens to prostate cancer growth. However, hypogonadism significantly affects quality of life and has negative sequelae, and the risks and benefits of testosterone therapy might be worthwhile to consider in all men, even those with a history of high-risk prostate cancer.To discuss the effects of testosterone (...) on the prostate and the use of testosterone therapy in hypogonadal men with a history of prostate cancer.Review of the literature examining the effects of testosterone on the prostate and the efficacy and safety of exogenous testosterone in men with a history of prostate cancer.Summary of effects of exogenous and endogenous testosterone on prostate tissue in vitro and in vivo, with a focus on effects in men with a history of prostate cancer.Testosterone therapy ameliorates the symptoms of hypogonadism

2016 Sexual medicine reviews

49. Is Testosterone Detrimental to Renal Function? Full Text available with Trip Pro

Is Testosterone Detrimental to Renal Function? 29318206 2019 02 26 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Is Testosterone Detrimental to Renal Function? 306-310 10.1016/j.ekir.2016.07.004 Filler Guido G Department of Paediatrics, Children's Hospital at London Health Science Centre, London, Ontario, Canada. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. Department of Medicine, University of Western Ontario

2016 Kidney international reports

50. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406358 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89-90 10.1056/NEJMc1603665 Laurent Michaël R MR KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Antonio Leen L KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Vanderschueren Dirk D KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406358 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA4

2016 NEJM

51. Testosterone Treatment in Older Men. (Abstract)

Testosterone Treatment in Older Men. 27406354 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 90 10.1056/NEJMc1603665 Snyder Peter J PJ Ellenberg Susan S SS Farrar John T JT eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):88 27406355 N Engl J Med. 2016 Jul 7;375(1):89-90 27406358 (...) N Engl J Med. 2016 Jul 7;375(1):88-9 27406356 N Engl J Med. 2016 Jul 7;375(1):89 27406357 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406354 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA5

2016 NEJM

52. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406355 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88 10.1056/NEJMc1603665 Perls Thomas T TT Boston University School of Medicine, Boston, MA thperls@bu.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug (...) therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406355 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA1

2016 NEJM

53. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406356 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88-9 10.1056/NEJMc1603665 Stavropoulos Konstantinos K Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Boutari Chrysoula C Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Imprialos Konstantinos K Aristotle University of Thessaloniki (...) , Thessaloniki, Greece kostasimprialos@hotmail.com. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406356 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA2

2016 NEJM

54. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406357 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89 10.1056/NEJMc1603665 Mata Douglas A DA Brigham and Women's Hospital, Boston, MA dmata@bwh.harvard.edu. Ramasamy Ranjith R University of Miami Miller School of Medicine, Miami, FL. Lipshultz Larry I LI Baylor College of Medicine, Houston, TX. eng Letter Comment United States N Engl J Med 0255562 0028-4793 (...) 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406357 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA3

2016 NEJM

55. Is Testosterone (T) treatment safe and effective in men with HIV infection? A meta-analysis Full Text available with Trip Pro

Is Testosterone (T) treatment safe and effective in men with HIV infection? A meta-analysis Is Testosterone (T) treatment safe and effective in men with HIV infection? A meta-analysis | ECE2016 | 18th European Congress of Endocrinology | Endocrine Abstracts Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online) Menu EP718 Endocrine Abstracts (2016) 41 EP718 | DOI: Is Testosterone (T) treatment safe and effective in men with HIV

2016 Endocrine Abstracts

56. Testosterone supplementation and body composition: results from a meta-analysis of observational studies Full Text available with Trip Pro

Testosterone supplementation and body composition: results from a meta-analysis of observational studies Testosterone supplementation and body composition: results from a meta-analysis of observational studies | ECE2016 | 18th European Congress of Endocrinology | Endocrine Abstracts Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online) Menu GP187 Endocrine Abstracts (2016) 41 GP187 | DOI: Testosterone supplementation and body (...) of Florence, Florence, Italy; 4 Department of Experimental and Clinical Medicine, University Magna Graecia, Rome, Italy; 5 Department of Experimental Medicine Sapienza, University of Rome, Rome, Italy; 6 Centre for Reproductive Medicine and Andrology, Munster, Germany; 7 Bayer Pharma, Global Medical Affairs Andrology, Berlin, Germany. Background: The concept of testosterone (T) supplementation (TS) as a new anti-obesity medication in men with testosterone deficiency syndrome (TDS) is emerging. Aim

2016 Endocrine Abstracts

57. Testosterone supplementation and body composition: results from a meta-analysis of randomized controlled trials Full Text available with Trip Pro

Testosterone supplementation and body composition: results from a meta-analysis of randomized controlled trials Testosterone supplementation and body composition: results from a meta-analysis of randomized controlled trials | ECE2016 | 18th European Congress of Endocrinology | Endocrine Abstracts Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online) Menu EP204 Endocrine Abstracts (2016) 41 EP204 | DOI: Testosterone (...) Sciences, University of Florence, Florence, Italy; 4 Department of Experimental Medicine Sapienza University of Rome, Rome, Italy; 5 Department of Experimental MDepartment of Experimental and Clinical Medicine, University Magna Graecia, Catanzaro, Italy; 6 Centre for Reproductive Medicine and Andrology, Munster, Germany; 7 Bayer Pharma, Global Medical Affairs Andrology, Berlin, Germany. Background: The role of testosterone (T) in regulating body composition is conflicting. Aim: To meta-analyze

2016 Endocrine Abstracts

58. Establishing a Framework - Does Testosterone Supplementation Help Older Men? (Abstract)

Establishing a Framework - Does Testosterone Supplementation Help Older Men? 26886526 2016 03 02 2018 12 02 1533-4406 374 7 2016 Feb 18 The New England journal of medicine N. Engl. J. Med. Establishing a Framework--Does Testosterone Supplementation Help Older Men? 682-3 10.1056/NEJMe1600196 Orwoll Eric S ES From the Department of Medicine, Oregon Health and Science University, Portland. eng Editorial Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J (...) Med. 2016 Feb 18;374(7):611-24 26886521 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 2 18 6 0 2016 2 18 6 0 2016 3 5 6 0 ppublish 26886526 10.1056/NEJMe1600196

2016 NEJM

59. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Rights OpenAccess. This work is licensed under a Creative

2016 PURLS

60. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy

Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn GA Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac and Henry G Burger Med J Aust 2016; 205 (4

2016 MJA Clinical Guidelines